Illinois Medicaid does not cover Wegovy or Zepbound for weight loss

Illinois Medicaid does not cover Wegovy or Zepbound for weight loss alone. The Preferred Drug List effective Oct. 1, 2026 lists Wegovy (pen and tablet) and Zepbound as non-preferred, covered only for cardiovascular risk and MASH (Wegovy) or sleep apnea (Zepbound). Saxenda and Foundayo are not on the list, and Illinois Medicaid health plans tell providers that obesity and weight loss are benefit exclusions under HFS.13

HFS has not published its own GLP-1 criteria on its criteria and forms page. Aetna Better Health of Illinois, an Illinois Medicaid health plan, publishes prior authorization criteria for Wegovy and Zepbound, effective Sept. 1, 2026, and states that use for weight loss only is an excluded benefit.24

• Wegovy (injection or tablet), cardiovascular path: an adult with established cardiovascular disease (previous heart attack, previous stroke, symptomatic peripheral arterial disease, or prior revascularization), a baseline BMI of at least 27, no type 2 diabetes, current guideline-directed cardiovascular therapy unless there is a clinical reason not to, and use with a reduced-calorie diet and more physical activity; approved for 12 months.
• Wegovy injection, MASH path: an adult with noncirrhotic MASH and moderate to advanced liver fibrosis (F2 to F3) confirmed by a non-invasive test or a past biopsy, prescribed by or with a gastroenterologist or hepatologist, used with diet and physical activity; approved for 12 months.
• Zepbound, sleep apnea path: an adult with moderate to severe obstructive sleep apnea (apnea-hypopnea index of at least 15 events per hour on a sleep study) and a current BMI of at least 30, used with diet and physical activity; initial approval 6 months, renewal 12 months with a positive response.
• Use of Wegovy or Zepbound for weight loss only is not covered.

Coverage for other uses the FDA has approved:

• Wegovy (injection), cardiovascular risk reduction in adults with cardiovascular disease and obesity or overweight: Covered with prior authorization12
• Wegovy (injection), MASH with moderate to advanced liver fibrosis (injection only): Covered with prior authorization12
• Wegovy tablets, cardiovascular risk reduction in adults with cardiovascular disease and obesity or overweight: Covered with prior authorization12
• Zepbound, moderate to severe obstructive sleep apnea with obesity: Covered with prior authorization12

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no HFS announcement that Illinois has joined.8

The CVS Caremark formulary for the Central Management Services state employee health plan, effective Nov. 1, 2026, lists Wegovy (pen and tablet), Wegovy HD, Zepbound, Foundayo and generic liraglutide under anti-obesity agents on tier 2, each requiring prior authorization. Separately, active employees can get a rebate of up to $200 once every three plan years toward an approved weight-loss program.91011

Pharmacy benefit: Illinois Department of Central Management Services; CVS Caremark (pharmacy benefit for the Open Access Plans, QCHP and CDHP; HMO members use their HMO's formulary).

Marketplace (ACA) plans: Illinois's essential health benefits benchmark plan for 2025 to 2027, a Blue Cross Blue Shield of Illinois small-group PPO, excludes drugs prescribed for obesity or weight loss.15

On the Preferred Drug List effective Oct. 1, 2026, Trulicity, Victoza and generic liraglutide are preferred; Rybelsus and the Ozempic tablets are preferred with prior authorization; the Ozempic pen and Mounjaro are non-preferred.13

In 2025, Illinois Medicaid paid for 271,913 GLP-1 prescriptions, $297.5 million before rebates: 21 per 1,000 residents, against 32 across the states and DC, 28th of 51.65 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 20 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4041313227352030

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2728292035363738393433
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.222420

In 2024, Medicare Part D drug plans paid for 702,606 GLP-1 claims from prescribers in Illinois, $909.5 million in total drug cost.66

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.70 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Illinois on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7172 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 0 outsourcing facilities (503B) in Illinois, as of November 6, 2026.67